1
|
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study. Eur Urol Oncol 2024:S2588-9311(24)00028-2. [PMID: 38296736 DOI: 10.1016/j.euo.2023.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 11/22/2023] [Accepted: 12/29/2023] [Indexed: 02/02/2024]
Abstract
BACKGROUND Androgen deprivation therapy (ADT), administered alone, as combined androgen blockade (CAB) or as ADT plus androgen receptor signalling inhibitors (ARSIs) or ADT plus docetaxel, is the standard treatment for metastatic hormone-naïve prostate cancer (mHNPC) in Japanese real-world practice. OBJECTIVE To investigate treatment patterns and clinical outcomes in LATITUDE criteria high-risk mHNPC. DESIGN, SETTING, AND PARTICIPANTS The longitudinal, multicentre, J-ROCK registry study enrolled patients initiating ADT in Japan after May 2019, and categorised them as cohort 1 (ADT or CAB) or cohort 2 (ADT plus ARSIs or docetaxel). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Prostate-specific antigen (PSA) response, progression-free survival (PFS), time to castrate-resistant prostate cancer (CRPC), overall survival (OS), and safety were evaluated. PFS, time to CRPC, and OS were estimated via the Kaplan-Meier method and between-cohort comparisons via multivariate Cox regression models. RESULTS AND LIMITATIONS In total, 974 patients were included (cohort 1: 38.1%, cohort 2: 61.9%). CAB was preferred (67.4%) to ADT alone in cohort 1, and abiraterone acetate plus prednisolone was used most frequently in cohort 2 (59.4%). The proportion of patients with ≥50%/≥90% PSA decline or who achieved PSA ≤0.2/≤0.1 ng/ml tended to be higher in cohort 2. PFS (adjusted hazard ratio 0.42; 95% confidence interval [CI] 0.31-0.55), time to CRPC (0.28; 95% CI 0.23-0.36), and OS (0.54; 95% CI 0.35-0.82) were longer in cohort 2. In cohorts 1 and 2, adverse drug reactions of special interest (ADRSIs) occurred in 1.3% and 15.1%, and fatal adverse events occurred in 1.9% and 1.7%, respectively. Limitations included nonrandomised design, varying time since marketing authorisation for ARSIs, and limited safety assessments. CONCLUSIONS ADT plus ARSIs or docetaxel was used more frequently to treat high-risk mHNPC than standard ADT/CAB and was associated with more favourable clinical outcomes. Although ADRSIs were reported more in cohort 2, the safety profile was considered tolerable. PATIENT SUMMARY Although many treatment options are available for high-risk metastatic prostate cancer, there are limited reports on real-world clinical experience with different therapies outside of the clinical trial setting. In this study, we compared clinical and safety outcomes with different treatment regimens, using a large series of patients with high-risk metastatic hormone-naïve prostate cancer across Japan. We found that androgen deprivation therapy in combination with newer androgen receptor signalling inhibitors resulted in improved response compared with androgen deprivation therapy alone or in combination with a first-generation antiandrogen.
Collapse
Affiliation(s)
- Hideaki Miyake
- Department of Urology, Hamamatsu University Hospital, Shizuoka, Japan
| | - Rikiya Matsumoto
- Department of Urology, Chutoen General Medical Center, Shizuoka, Japan
| | - Kiyohide Fujimoto
- Department of Urology, Nara Medical University Hospital, Nara, Japan
| | - Atsushi Mizokami
- Department of Urology, Kanazawa University Hospital, Ishikawa, Japan
| | | | - Toshiyuki Kamoto
- Department of Urology, University of Miyazaki Hospital, Miyazaki, Japan
| | - Satoru Kawakami
- Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
| | | | | | - Kazuhiro Shibayama
- Statistics & Decision Sciences Japan, Janssen Pharmaceutical K.K., Tokyo, Japan
| | - Aki Watanabe
- Medical Affairs Operations, Global Development, Janssen R&D, Tokyo, Japan
| | - Miku Ito
- Department of Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan
| | - Yohei Tajima
- Department of Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan
| | | | - Hiroji Uemura
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa, Japan
| |
Collapse
|
2
|
Lin C, Ahn JK, Choi JM, Farrington MS, Gonzalez M, Grethen N, Hsiung YB, Inagaki T, Kamiji I, Kim EJ, Kim JL, Kim HM, Kawata K, Kitagawa A, Komatsubara TK, Kotera K, Lee SK, Lee JW, Lim GY, Luo Y, Matsumura T, Nakagiri K, Nanjo H, Nomura T, Ono K, Redeker JC, Sato T, Sasse V, Shibata T, Shimizu N, Shinkawa T, Shinohara S, Shiomi K, Shiraishi R, Suzuki S, Tajima Y, Tung YC, Wah YW, Watanabe H, Wu T, Yamanaka T, Yoshida HY. Search for the Pair Production of Dark Particles X with K_{L}^{0}→XX, X→γγ. Phys Rev Lett 2023; 130:111801. [PMID: 37001070 DOI: 10.1103/physrevlett.130.111801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Accepted: 02/08/2023] [Indexed: 06/19/2023]
Abstract
We present the first search for the pair production of dark particles X via K_{L}^{0}→XX with X decaying into two photons using the data collected by the KOTO experiment. No signal was observed in the mass range of 40-110 MeV/c^{2} and 210-240 MeV/c^{2}. This sets upper limits on the branching fractions as B(K_{L}^{0}→XX)<(1-4)×10^{-7} and B(K_{L}^{0}→XX)<(1-2)×10^{-6} at the 90% confidence level for the two mass regions, respectively.
Collapse
Affiliation(s)
- C Lin
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - J M Choi
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - M S Farrington
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - M Gonzalez
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - N Grethen
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - T Inagaki
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - I Kamiji
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - E J Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - J L Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - H M Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - K Kawata
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - A Kitagawa
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T K Komatsubara
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - K Kotera
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S K Lee
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - J W Lee
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - G Y Lim
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - Y Luo
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - T Matsumura
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - K Nakagiri
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Nanjo
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Nomura
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - K Ono
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - J C Redeker
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - T Sato
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - V Sasse
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - T Shibata
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - N Shimizu
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Shinkawa
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - S Shinohara
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - K Shiomi
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - R Shiraishi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Suzuki
- Department of Physics, Saga University, Saga 840-8502, Japan
| | - Y Tajima
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - Y-C Tung
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - Y W Wah
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - H Watanabe
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - T Wu
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - T Yamanaka
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Y Yoshida
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| |
Collapse
|
3
|
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M. Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2021; 51:1770. [PMID: 34585728 PMCID: PMC8643447 DOI: 10.1093/jjco/hyab161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 07/05/2021] [Indexed: 12/05/2022] Open
Affiliation(s)
- Yoshihiko Tomita
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan
| | - Go Kimura
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
| | - Satoshi Fukasawa
- Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan
| | - Kazuyuki Numakura
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Kazutoshi Yamana
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan
| | - Sei Naito
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
| | | | | | - Mototsugu Oya
- Department of Urology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
4
|
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kaneko H, Tajima Y, Oya M. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2021; 51:1656-1664. [PMID: 34350454 PMCID: PMC8558912 DOI: 10.1093/jjco/hyab114] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 07/05/2021] [Indexed: 11/13/2022] Open
Abstract
Background We performed subgroup analyses of the AFTER I-O study to clarify the association of time-to-treatment failure (TTF) and discontinuation reason of prior immune-oncology (I-O) therapy, and molecular targeted therapy (TT) regimen with the outcomes of TT after I-O. Methods The data of Japanese metastatic renal cell carcinoma patients treated with TT after nivolumab (NIVO) (CheckMate 025) or NIVO + ipilimumab (IPI) (CheckMate 214) were retrospectively analyzed. The objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS) of TT after I-O were analyzed by subgroups: TTF (<6 or ≥6 months) and discontinuation reason of prior I-O (progression or adverse events), and TT regimen (sunitinib or axitinib). We also analyzed PFS2 of prior I-O and OS from first-line therapy. Results The ORR and median PFS of TT after NIVO and NIVO+IPI among the subgroups was 17–36% and 20–44%, and 7.1–11.6 months and 16.3-not reached (NR), respectively. The median OS of TT after NIVO was longer in patients with longer TTF of NIVO and treated with axitinib. Conversely, median OS of TT after NIVO+IPI was similar among subgroups. The median PFS2 of NIVO and NIVO+IPI was 36.7 and 32.0 months, respectively. The median OS from first-line therapy was 70.5 months for patients treated with NIVO and NR with NIVO+IPI. The safety profile of each TT after each I-O was similar to previous reports. Conclusions The efficacy of TT after NIVO or NIVO+IPI was favorable regardless of the TTF and discontinuation reason of prior I-O, and TT regimen.
Collapse
Affiliation(s)
- Yoshihiko Tomita
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan
| | - Go Kimura
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
| | - Satoshi Fukasawa
- Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan
| | - Kazuyuki Numakura
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Kazutoshi Yamana
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan
| | - Sei Naito
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
| | | | | | - Mototsugu Oya
- Department of Urology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Jpn J Clin Oncol 2021; 51:966-975. [PMID: 33594427 PMCID: PMC8163064 DOI: 10.1093/jjco/hyaa266] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 12/22/2020] [Indexed: 12/20/2022] Open
Abstract
Objectives Guidelines for treatment of mRCC recommend nivolumab monotherapy (NIVO) for treated patients, and nivolumab plus ipilimumab combination therapy (NIVO+IPI) for untreated IMDC intermediate and poor-risk mRCC patients. Although molecular-targeted therapies (TTs) such as VEGFR-TKIs and mTORi are recommended as subsequent therapy after NIVO or NIVO+IPI, their efficacy and safety remain unclear. Methods Outcome of Japanese patients with mRCC who received TT after NIVO (CheckMate 025) or NIVO+IPI (CheckMate 214) were retrospectively analyzed. Primary endpoints were investigator-assessed ORR of the first TT after either NIVO or NIVO+IPI. Secondary endpoints included TFS, PFS, OS and safety of TTs. Results Twenty six patients in CheckMate 025 and 19 patients in CheckMate 214 from 20 centers in Japan were analyzed. As the first subsequent TT after NIVO or NIVO+IPI, axitinib was the most frequently treated regimen for both CheckMate 025 (54%) and CheckMate 214 (47%) patients. The ORRs of TT after NIVO and NIVO+IPI were 27 and 32% (all risks), and median PFSs were 8.9 and 16.3 months, respectively. During the treatment of first TT after either NIVO or NIVO+IPI, 98% of patients experienced treatment-related adverse events, including grade 3–4 events in 51% of patients, and no treatment-related deaths occurred. Conclusions TTs have favorable antitumor activity in patients with mRCC after ICI, possibly via changing the mechanism of action. Safety signals of TTs after ICI were similar to previous reports. These results indicate that sequential TTs after ICI may contribute for long survival benefit.
Collapse
Affiliation(s)
- Yoshihiko Tomita
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - Go Kimura
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
| | | | - Kazuyuki Numakura
- Department of Urology, Akita University School of Medicine, Akita, Japan
| | - Yutaka Sugiyama
- Department of Urology, Graduate School of Medical Sciences, Kumamoto, Japan
| | - Kazutoshi Yamana
- Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata, Japan
| | - Sei Naito
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
| | - Koki Kabu
- Bristol-Myers Squibb, Shinjuku-ku, Tokyo, Japan
| | | | - Mototsugu Oya
- Department of Urology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
6
|
Ahn JK, Beckford B, Campbell M, Chen SH, Comfort J, Dona K, Farrington MS, Hanai K, Hara N, Haraguchi H, Hsiung YB, Hutcheson M, Inagaki T, Isoe M, Kamiji I, Kato T, Kim EJ, Kim JL, Kim HM, Komatsubara TK, Kotera K, Lee SK, Lee JW, Lim GY, Lin QS, Lin C, Luo Y, Mari T, Masuda T, Matsumura T, Mcfarland D, McNeal N, Miyazaki K, Murayama R, Nakagiri K, Nanjo H, Nishimiya H, Noichi Y, Nomura T, Nunes T, Ohsugi M, Okuno H, Redeker JC, Sanchez J, Sasaki M, Sasao N, Sato T, Sato K, Sato Y, Shimizu N, Shimogawa T, Shinkawa T, Shinohara S, Shiomi K, Shiraishi R, Su S, Sugiyama Y, Suzuki S, Tajima Y, Taylor M, Tecchio M, Togawa M, Toyoda T, Tung YC, Vuong QH, Wah YW, Watanabe H, Yamanaka T, Yoshida HY, Zaidenberg L. Study of the K_{L}→π^{0}νν[over ¯] Decay at the J-PARC KOTO Experiment. Phys Rev Lett 2021; 126:121801. [PMID: 33834796 DOI: 10.1103/physrevlett.126.121801] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 02/18/2021] [Indexed: 06/12/2023]
Abstract
The rare decay K_{L}→π^{0}νν[over ¯] was studied with the dataset taken at the J-PARC KOTO experiment in 2016, 2017, and 2018. With a single event sensitivity of (7.20±0.05_{stat}±0.66_{syst})×10^{-10}, three candidate events were observed in the signal region. After unveiling them, contaminations from K^{±} and scattered K_{L} decays were studied, and the total number of background events was estimated to be 1.22±0.26. We conclude that the number of observed events is statistically consistent with the background expectation. For this dataset, we set an upper limit of 4.9×10^{-9} on the branching fraction of K_{L}→π^{0}νν[over ¯] at the 90% confidence level.
Collapse
Affiliation(s)
- J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - B Beckford
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Campbell
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - S H Chen
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - J Comfort
- Department of Physics, Arizona State University, Tempe, Arizona 85287, USA
| | - K Dona
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M S Farrington
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - K Hanai
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - N Hara
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Haraguchi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - M Hutcheson
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - T Inagaki
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Isoe
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - I Kamiji
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Kato
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - E J Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - J L Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - H M Kim
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - T K Komatsubara
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - K Kotera
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S K Lee
- Division of Science Education, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - J W Lee
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - G Y Lim
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - Q S Lin
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - C Lin
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - Y Luo
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - T Mari
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Masuda
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - T Matsumura
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - D Mcfarland
- Department of Physics, Arizona State University, Tempe, Arizona 85287, USA
| | - N McNeal
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - K Miyazaki
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - R Murayama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - K Nakagiri
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Nanjo
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Nishimiya
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Noichi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Nomura
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - T Nunes
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Ohsugi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Okuno
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - J C Redeker
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - J Sanchez
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Sasaki
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - N Sasao
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - T Sato
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - K Sato
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Sato
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - N Shimizu
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Shimogawa
- Department of Physics, Saga University, Saga 840-8502, Japan
| | - T Shinkawa
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - S Shinohara
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - K Shiomi
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - R Shiraishi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Su
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - Y Sugiyama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Suzuki
- Department of Physics, Saga University, Saga 840-8502, Japan
| | - Y Tajima
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - M Taylor
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Tecchio
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Togawa
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Toyoda
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y-C Tung
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - Q H Vuong
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y W Wah
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - H Watanabe
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - T Yamanaka
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Y Yoshida
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - L Zaidenberg
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| |
Collapse
|
7
|
Ishida A, Tajima Y, Okabe Y, Matsushita T, Sekiguchi T, Imaide S, Nomura Y, Tanaka M, Nojima S, Yoshida A, Iyoda Y, Aoki S, Nishio T, Komagata T, Iwaki M, Shono T, Naganawa A, Imagawa A. Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly. ACS Chem Neurosci 2020; 11:1482-1494. [PMID: 32315148 DOI: 10.1021/acschemneuro.0c00124] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Acromegaly is a disease caused by the oversecretion of growth hormone. It is currently treated by intravenous injection with cyclic peptide drugs that activate somatostatin receptor subtype 2 (SSTR2). Here, novel nonpeptidic, small-molecule, and orally active SSTR2 agonists were identified from a hit compound (13). Pharmacophore studies enabled scaffold hopping to obtain a unique 3,4,5-trisubstituted pyridine motif. Further optimization conferred potent SSTR2 agonistic activity and metabolic stability. Several compounds were evaluated and these showed good oral pharmacokinetic profiles in rats, and one representative compound (25) showed highly potent inhibition of growth hormone secretion induced by growth hormone-releasing hormone in rats. Based on these results, 25 was identified as a promising lead for further optimization. A structure-activity relationship (SAR) study and the metabolic stability data for this compound are also described.
Collapse
Affiliation(s)
- Akiharu Ishida
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Yohei Tajima
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Yasuyuki Okabe
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Takeshi Matsushita
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Tetsuya Sekiguchi
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Satomi Imaide
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Yoshinori Nomura
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Motoyuki Tanaka
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Shoji Nojima
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Atsushi Yoshida
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Yoko Iyoda
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Shohei Aoki
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Takuya Nishio
- Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
| | - Tatsuya Komagata
- Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
| | - Masanori Iwaki
- Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
| | - Tomoyuki Shono
- Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
| | - Atsushi Naganawa
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| | - Akira Imagawa
- Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan
| |
Collapse
|
8
|
Tomita Y, Kimura G, Fukasawa S, Sugiyama Y, Numakura K, Yamana K, Naito S, Kabu K, Tajima Y, Oya M. Treatment-free survival after discontinuation of immuno-checkpoint therapy, and outcome of subsequent molecular targeted therapy: Retrospective study of Japanese metastatic renal cell carcinoma patients (after I-O study). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
677 Background: Guidelines for treatment of metastatic renal cell carcinoma (mRCC) recommend nivolumab monotherapy (NIVO) for treated mRCC, and nivolumab + ipilimumab combination therapy (NIVO+IPI) for untreated IMDC intermediate and poor risk mRCC patients. Though molecular targeted therapies (TTs) such as VEGFR-TKIs and mTORi are recommended as subsequent therapy after NIVO or NIVO+IPI, their impact is still unclear. Methods: Japanese mRCC patients treated with TT after NIVO (CheckMate 025) or NIVO+IPI (CheckMate 214) were retrospectively analyzed. Primary endpoints were investigator assessed ORR of the first TT after NIVO, and after NIVO+IPI. Secondary endpoints included treatment-free survival (TFS) after discontinuation of NIVO and NIVO+IPI, and progression-free survival (PFS) and safety of the first subsequent TT after NIVO and NIVO+IPI. Results: Twenty-six patients of CheckMate 025 and 19 patients of CheckMate 214 from 20 centers in Japan were analyzed. Median TFS after ICI discontinuation was 1.0m and 2.5m for CheckMate 025 and CheckMate 214 patients, respectively. Median follow-up period from the start of TT after ICI discontinuation to date of analysis or death was 22.1m for CheckMate 025, and 20.3m for CheckMate 214 patients. As the first subsequent TT after NIVO or NIVO+IPI, axitinib was the most treated therapy for both CheckMate 025 (53.8%) and CheckMate 214 (47.4%) patients. ORR of TT after NIVO and NIVO+IPI was 26.9% and 31.6%, and median PFS was 8.9m and 16.3m, respectively. During the treatment of first TT after NIVO and NIVO+IPI, 98% percent experienced treated-related adverse events, 51% experienced grade 3-4, but no treatment related death. Conclusions: TTs have favorable antitumor activity for mRCC after NIVO and NIVO+IPI, possibly by changing the mode of action. Safety signals of TTs after ICI were similar to the previous reports. These results indicate sequential TTs after ICI may contribute for durable survival benefit.
Collapse
Affiliation(s)
- Yoshihiko Tomita
- Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Go Kimura
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
| | | | - Yutaka Sugiyama
- Department of Urology, Kumamoto University Faculty of Life Sciences, Kumamoto, Japan
| | | | | | - Sei Naito
- Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
| | - Koki Kabu
- Bayer Ltd. Medical Affairs, Oncology and Hematology, Tokyo, Japan
| | | | | |
Collapse
|
9
|
Katashkina JI, Kazieva ED, Tajima Y, Mashko SV. Increased Isoprene Production by the Recombinant Pantoea ananatis Strain due to the Balanced Amplification of Mevalonate Pathway Genes. APPL BIOCHEM MICRO+ 2019. [DOI: 10.1134/s0003683819090023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
10
|
Nitta N, Tajima Y, Katashkina J, Yamamoto Y, Onuki A, Rachi H, Kazieva E, Nishio Y. Application of inorganic phosphate limitation to efficient isoprene production in
Pantoea ananatis. J Appl Microbiol 2019; 128:763-774. [DOI: 10.1111/jam.14521] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 11/08/2019] [Accepted: 11/15/2019] [Indexed: 01/11/2023]
Affiliation(s)
- N. Nitta
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| | - Y. Tajima
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| | | | - Y. Yamamoto
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| | - A. Onuki
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| | - H. Rachi
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| | - E. Kazieva
- Ajinomoto‐Genetika Research Institute Moscow Russia
| | - Y. Nishio
- Institute for Innovation Ajinomoto Co., Inc. Kawasaki Japan
| |
Collapse
|
11
|
Oya M, Tajima Y, Kabu K. [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma]. Gan To Kagaku Ryoho 2019; 46:1397-1404. [PMID: 31530779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The International Metastatic Renal Cell Carcinoma Database Consortium(IMDC)classification is often used to predict the prognosis of patients treated with molecularly targeted agents. In this review, the authors describe the prognostic value of the neutrophil-lymphocyte ratio and C-reactive protein for Japanese patients with renal cell carcinoma. Both markers may help identify which patients are likely to have a poor prognosis despite molecularly targeted therapy. In these circumstances, the CheckMate 214 trial showed that nivolumab plus ipilimumab combination therapy was superior to sunitinib for the treatment of patients with intermediate/poor prognosis. As a consequence, the combination of nivolumab plus ipilimumab is now positioned as standard first-line treatment for renal cell carcinoma, and the IMDCclassification is recommended as an aid in treatment decisions. Although careful management of immune-related adverse events is necessary, nivolumab plus ipilimumab combination therapy is expected to improve the outcomes of renal cell carcinoma for which the prognosis is otherwise generally poor.
Collapse
Affiliation(s)
- Mototsugu Oya
- Dept. of Urology, Keio University School of Medicine
| | | | | |
Collapse
|
12
|
Shimozono T, Tajima Y, Akamatsu S, Matsuba Y, Kawasaki A. Large-Scale Channel Migration in the Sittang River Estuary. Sci Rep 2019; 9:9862. [PMID: 31285481 PMCID: PMC6614478 DOI: 10.1038/s41598-019-46300-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 06/26/2019] [Indexed: 11/24/2022] Open
Abstract
An estuary is a dynamic environment where marine and fluvial processes meet to form complex and transient morphology. The estuary morphology is largely determined by net sediment transport by two-way tidal flows, but the hydrodynamics also depends on the morphology of the tidal channels. The estuary inherently accommodates cyclic processes that are internally generated through hydro-morphodynamic interactions. In addition, the estuary evolves in response to changes in external forces by natural and anthropogenic factors. Morphological changes under the different controls often hinder the comprehension of the evolutionary processes of estuaries. Here we explored morphological changes in the Sittang River estuary, Myanmar, which has great morphological dynamism from extreme tidal energy and large sediment inputs, through field surveys and satellite imagery analysis. We identify an autocyclic process in a sedimentary system driving large-scale channel migration in decadal to multidecadal cycles. We show that drastic changes of the estuary morphology occasionally occur with rapid bank erosion through modulation of the cyclic channel migration under conflicting tidal and fluvial forces. This extreme case with minimal human intervention highlights channel migration as a key process in morphological evolution of tide-dominated estuaries undergoing active infilling.
Collapse
Affiliation(s)
- T Shimozono
- Department of Civil Engineering, University of Tokyo, Tokyo, Japan.
| | - Y Tajima
- Department of Civil Engineering, University of Tokyo, Tokyo, Japan
| | - S Akamatsu
- Department of Civil Engineering, University of Tokyo, Tokyo, Japan
| | - Y Matsuba
- Department of Civil Engineering, University of Tokyo, Tokyo, Japan
| | - A Kawasaki
- Department of Civil Engineering, University of Tokyo, Tokyo, Japan
| |
Collapse
|
13
|
Ahn JK, Beckford B, Beechert J, Bryant K, Campbell M, Chen SH, Comfort J, Dona K, Hara N, Haraguchi H, Hsiung YB, Hutcheson M, Inagaki T, Kamiji I, Kawasaki N, Kim EJ, Kim JL, Kim YJ, Ko JW, Komatsubara TK, Kotera K, Kurilin AS, Lee JW, Lim GY, Lin C, Lin Q, Luo Y, Ma J, Maeda Y, Mari T, Masuda T, Matsumura T, Mcfarland D, McNeal N, Micallef J, Miyazaki K, Murayama R, Naito D, Nakagiri K, Nanjo H, Nishimiya H, Nomura T, Ohsugi M, Okuno H, Sasaki M, Sasao N, Sato K, Sato T, Sato Y, Schamis H, Seki S, Shimizu N, Shimogawa T, Shinkawa T, Shinohara S, Shiomi K, Su S, Sugiyama Y, Suzuki S, Tajima Y, Taylor M, Tecchio M, Togawa M, Tung YC, Wah YW, Watanabe H, Woo JK, Yamanaka T, Yoshida HY. Search for K_{L}→π^{0}νν[over ¯] and K_{L}→π^{0}X^{0} Decays at the J-PARC KOTO Experiment. Phys Rev Lett 2019; 122:021802. [PMID: 30720307 DOI: 10.1103/physrevlett.122.021802] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 12/14/2018] [Indexed: 06/09/2023]
Abstract
A search for the rare decay K_{L}→π^{0}νν[over ¯] was performed. With the data collected in 2015, corresponding to 2.2×10^{19} protons on target, a single event sensitivity of (1.30±0.01_{stat}±0.14_{syst})×10^{-9} was achieved and no candidate events were observed. We set an upper limit of 3.0×10^{-9} for the branching fraction of K_{L}→π^{0}νν[over ¯] at the 90% confidence level (C.L.), which improved the previous limit by almost an order of magnitude. An upper limit for K_{L}→π^{0}X^{0} was also set as 2.4×10^{-9} at the 90% C.L., where X^{0} is an invisible boson with a mass of 135 MeV/c^{2}.
Collapse
Affiliation(s)
- J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - B Beckford
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - J Beechert
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - K Bryant
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Campbell
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - S H Chen
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - J Comfort
- Department of Physics, Arizona State University, Tempe, Arizona 85287, USA
| | - K Dona
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - N Hara
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Haraguchi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y B Hsiung
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - M Hutcheson
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - T Inagaki
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - I Kamiji
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - N Kawasaki
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - E J Kim
- Division of Science Education, Chonbuk National University, Jeonju 54896, Republic of Korea
| | - J L Kim
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - Y J Kim
- Department of Physics, Jeju National University, Jeju 63243, Republic of Korea
| | - J W Ko
- Department of Physics, Jeju National University, Jeju 63243, Republic of Korea
| | - T K Komatsubara
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - K Kotera
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - A S Kurilin
- Laboratory of Nuclear Problems, Joint Institute for Nuclear Researches, Dubna, Moscow region 141980, Russia
| | - J W Lee
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - G Y Lim
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - C Lin
- Department of Physics, National Taiwan University, Taipei, Taiwan 10617, Republic of China
| | - Q Lin
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - Y Luo
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - J Ma
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - Y Maeda
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Mari
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Masuda
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - T Matsumura
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - D Mcfarland
- Department of Physics, Arizona State University, Tempe, Arizona 85287, USA
| | - N McNeal
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - J Micallef
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - K Miyazaki
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - R Murayama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - D Naito
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - K Nakagiri
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Nanjo
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Nishimiya
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Nomura
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - M Ohsugi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Okuno
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Sasaki
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - N Sasao
- Research Institute for Interdisciplinary Science, Okayama University, Okayama 700-8530, Japan
| | - K Sato
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Sato
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - Y Sato
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Schamis
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - S Seki
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - N Shimizu
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Shimogawa
- Department of Physics, Saga University, Saga 840-8502, Japan
| | - T Shinkawa
- Department of Applied Physics, National Defense Academy, Kanagawa 239-8686, Japan
| | - S Shinohara
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - K Shiomi
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - S Su
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - Y Sugiyama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Suzuki
- Department of Physics, Saga University, Saga 840-8502, Japan
| | - Y Tajima
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - M Taylor
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Tecchio
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109, USA
| | - M Togawa
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y C Tung
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - Y W Wah
- Enrico Fermi Institute, University of Chicago, Chicago, Illinois 60637, USA
| | - H Watanabe
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
- J-PARC Center, Tokai, Ibaraki 319-1195, Japan
| | - J K Woo
- Department of Physics, Jeju National University, Jeju 63243, Republic of Korea
| | - T Yamanaka
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - H Y Yoshida
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| |
Collapse
|
14
|
Takakura Y, Otsuki M, Nakagawa Y, Tajima Y, Mito Y, Ogata A, Koshimizu S, Yoshino M, Uemori G. Comparative symptomatology of apraxia of speech/anarthrie: Patients with neurodegenerative diseases versus cerebrovascular diseases. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Otsuki M, Nakagawa Y, Kondo K, Houzen H, Hamada S, Tajima Y, Mito Y, Koshimizu S, Ogata A, Ura S, Kuroshima K, Yoshida K, Yabe I, Sasaki H. Longitudinal investigation of the symptoms and the imaging findings of nfvPPA:: Sub-classification for nosology. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Hirahara N, Matsubara T, Kawahara D, Nakada S, Ishibashi S, Tajima Y. Prognostic significance of preoperative inflammatory response biomarkers in patients undergoing curative thoracoscopic esophagectomy for esophageal squamous cell carcinoma. Eur J Surg Oncol 2016; 43:493-501. [PMID: 28034501 DOI: 10.1016/j.ejso.2016.11.018] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Revised: 10/10/2016] [Accepted: 11/30/2016] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Recent studies have revealed significant relationships between the lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) and survival in various cancers. The purpose of this study was to confirm whether the LMR, NLR, and PLR have prognostic values, independent of clinicopathological criteria, in patients undergoing curative resection for esophageal cancer. METHODS The LMR, NLR and PLR were calculated in 147 consecutive patients who underwent curative esophagectomy between January 2006 and December 2014. Receiver operating characteristics (ROC) curve analysis was conducted to identify the optimal cutoff values of each biomarkers. RESULTS In multivariate analysis for cancer-specific survival (CSS), pTNM stage (p < 0.0001) and low LMR (p = 0.0081) were selected as independent prognostic factor. Similarly, pTNM stage(p < 0.0001) and low LMR (p = 0.0225) were found to be independent prognostic factor for overall survival (OS). There was no significant relationship between LMR, NLR and PLR and survival in patients with stage I or II, however, significant relationships between LMR and CSS or OS were observed in patients with stage III esophageal cancer. CONCLUSIONS LMR can be used as a novel predictor of postoperative CSS and OS in patients with esophageal cancer and that it may be useful in identifying patients with a poor prognosis even after radical esophagectomy.
Collapse
Affiliation(s)
- N Hirahara
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan.
| | - T Matsubara
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan
| | - D Kawahara
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan
| | - S Nakada
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan
| | - S Ishibashi
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan
| | - Y Tajima
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, Japan
| |
Collapse
|
17
|
Kawabata Y, Tanaka T, Ishikawa N, Hayashi H, Tajima Y. Modified total meso-pancreatoduodenum excision with pancreaticoduodenectomy as a mesopancreatic plane surgery in borderline resectable pancreatic cancer. Eur J Surg Oncol 2016; 42:698-705. [PMID: 26995116 DOI: 10.1016/j.ejso.2016.02.241] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Revised: 02/09/2016] [Accepted: 02/12/2016] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND A superior mesenteric artery (SMA)-first approach has been considered to be an efficient technique in pancreaticoduodenectomy when the SMA is a factor of borderline resectable pancreatic head cancer (BRPHC). However, this excellent procedure has limitations in terms of tumor resection with an intact coverage including the pancreatic tumor and the tumor-draining lymphovascular systems and the ability to achieve a complete regional lymphadenectomy. METHODS A modified mesenteric plane procedure has been developed that provides improved regional lymphadenectomy and permits adjustment of the surgical approach, which is based on the direction of the tumor infiltration. RESULTS Of 55 patients taken to surgery, 19 had peritoneal dissemination and/or liver metastasis at staging laparoscopy, and the procedure revealed tumor infiltration to the SMA and/or hepatic artery (HA) in 4 patients. Finally, 32 patients with BRPHC have undergone the procedure between April 2009 and June 2015. Twenty-four of 32 patients (75.0%) had negative resection margins, and the median number of lymph nodes harvested was 34. Lymph nodes around the SMA tested positive for metastasis in 13 patients (40.6%), and those around the HA tested positive for metastasis in 7 patients (21.9%). Complications occurred in 14 patients (43.7%), with no perioperative mortality. Overall survival rates were 65.3% at 1 year and 35.2% at 3 years. CONCLUSIONS Short-term results with the procedure may encourage surgical management for BRPHC.
Collapse
Affiliation(s)
- Y Kawabata
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan.
| | - T Tanaka
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan
| | - N Ishikawa
- Department of Organ Pathology, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan
| | - H Hayashi
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan
| | - Y Tajima
- Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enyacho, Izumo, Shimane, 693-8501, Japan
| |
Collapse
|
18
|
He Q, Fujimura H, Fukasawa H, Hashimoto R, Honda Y, Ishikawa T, Iwata T, Kaida S, Kasagi J, Kawano A, Kuwasaki S, Maeda K, Masumoto S, Miyabe M, Miyahara F, Mochizuki K, Muramatsu N, Nakamura A, Nawa K, Ogushi S, Okada Y, Onodera Y, Ozawa K, Sakamoto Y, Sato M, Shimizu H, Sugai H, Suzuki K, Tajima Y, Takahashi S, Taniguchi Y, Tsuchikawa Y, Yamazaki H, Yamazaki R, Yoshida HY. Double neutral pion photoproduction off the proton with FOREST at ELPH. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201610904004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Shiraishi S, Nakayama H, Itonaga T, Tajima Y, Okubo M, Mikami R, Tokuuye K. Risk of Symptomatic Radiation Pneumonitis After Thoracic Radiation Therapy in Patients With a Reticular Shadow. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Impact of inflammation-based prognostic score on survival after curative thoracoscopic esophagectomy for esophageal cancer. Eur J Surg Oncol 2015; 41:1308-15. [DOI: 10.1016/j.ejso.2015.07.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2015] [Revised: 05/09/2015] [Accepted: 07/09/2015] [Indexed: 01/06/2023] Open
|
21
|
Yoshida Y, Yamazaki K, Mizusawa J, Satoh M, Hinoi T, Tsuchida A, Otsuka K, Sato T, Watanabe M, Baba H, Kimura H, Idani H, Kanazawa A, Fukunaga M, Okuda J, Tajima Y, Hasegawa H, Katayama H, Hamaguchi T, Shimada Y. 2129 Predictive factor for toxicities and treatment termination in adjuvant capecitabine therapy for stage III colorectal cancer; based on the data of a randomized trial, JCOG0910. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31051-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
22
|
Itadani S, Yashiro K, Aratani Y, Sekiguchi T, Kinoshita A, Moriguchi H, Ohta N, Takahashi S, Ishida A, Tajima Y, Hisaichi K, Ima M, Ueda J, Egashira H, Sekioka T, Kadode M, Yonetomi Y, Nakao T, Inoue A, Nomura H, Kitamine T, Fujita M, Nabe T, Yamaura Y, Matsumura N, Imagawa A, Nakayama Y, Takeuchi J, Ohmoto K. Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma. J Med Chem 2015. [PMID: 26200813 DOI: 10.1021/acs.jmedchem.5b00741] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Takeshi Nabe
- ∥Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge, Hirakata, Osaka 573-0101, Japan.,⊥Department of Pharmacology, Kyoto Pharmaceutical University, 5 Nakauchi Misasagi, Yamashina, Kyoto 607-8414, Japan
| | | | | | | | | | | | | |
Collapse
|
23
|
Tajima Y, Nakayama H, Itonaga T, Shiraishi S, Okubo M, Mikami R, Sugahara S, Tokuuye K. Dosimetric evaluation of compensator intensity modulation-based stereotactic body radiotherapy for Stage I non-small-cell lung cancer. Br J Radiol 2015; 88:20150122. [PMID: 25996577 DOI: 10.1259/bjr.20150122] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE To evaluate the dosimetry of compensator intensity modulation-based stereotactic body radiotherapy (SBRT) [non-coplanar intensity-modulated radiotherapy (ncIMRT)], its use was compared with that of three-dimensional conformation-based SBRT, for patients with Stage I non-small-cell lung cancer (NSCLC). METHODS 21 consecutive patients with Stage I NSCLC were treated with ncIMRT or SBRT at Tokyo Medical University. To compare the two techniques, ncIMRT and SBRT plans for each patient were generated, where the planning target volume (PTV) coverages were adjusted to be equivalent to each other. The prescribed dose was set as 75 Gy in 30 fractions. PTV coverage, conformity index, conformation number (CN) and homogeneity index (HI) were used to compare the two strategies. RESULTS There was no statistically significant difference between PTV coverage for the 100%, 95% and 90% dose levels in the SBRT plan and those in the ncIMRT plan. The CN values were 0.53 ± 0.13 in the SBRT plan and 0.72 ± 0.10 in the ncIMRT plan. These values were significantly better than those of the SBRT plan (p < 0.001). The HI in the ncIMRT plan was 1.04 ± 0.03%, which was also significantly better than that of SBRT. CONCLUSION The ncIMRT plan provided superior conformity and reduced the doses to the lung for patients with Stage I NSCLC. ADVANCES IN KNOWLEDGE The delivery technique with compensator intensity modulation-based SBRT was evaluated. Concerning target motion, this is thought to be more robust and safer than SBRT for early-stage NSCLC.
Collapse
Affiliation(s)
- Y Tajima
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - H Nakayama
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - T Itonaga
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - S Shiraishi
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - M Okubo
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - R Mikami
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - S Sugahara
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| | - K Tokuuye
- Department of Radiology, Tokyo Medical University, Tokyo, Japan
| |
Collapse
|
24
|
Ishijima M, Nakayama H, Itonaga T, Tajima Y, Shiraishi S, Okubo M, Mikami R, Tokuuye K. Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy. Br J Radiol 2014; 88:20140596. [PMID: 25490255 DOI: 10.1259/bjr.20140596] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVE To evaluate the risk of radiation pneumonitis (RP) after stereotactic radiotherapy (SBRT) for patients presenting with severe pulmonary emphysema. METHODS This study included 40 patients with Stage I non-small-cell lung cancer who underwent SBRT, 75 Gy given in 30 fractions, at the Tokyo Medical University, Tokyo, Japan, between February 2010 and February 2013. The median age of the patients was 79 years (range, 49-90 years), and the male:female ratio was 24:16. There were 20 T1 and 20 T2 tumours. 17 patients had emphysema, 6 had slight interstitial changes on CT images and the remaining 17 had no underlying lung disease. The level of emphysema was classified into three groups according to the modified Goddard's criteria (severe: three patients, moderate: eight patients and mild: six patients). Changes in the irradiated lung following SBRT were evaluated by CT. RESULTS On CT images, RP was detected in 34 (85%) patients, and not in 6 (15%) patients, during a median observation period of 313 days. Of the six patients, three had severe emphysema and three had no underlying lung disease. Patients with severe emphysema had lower risk of RP than those with moderate emphysema (p = 0.01), mild emphysema (p = 0.04) and no underlying lung disease (p = 0.01). CONCLUSION Patients with severe emphysema had a low risk of RP following SBRT. ADVANCES IN KNOWLEDGE Little is known about the association between RP and pulmonary emphysema. Patients with severe emphysema had lower risk of RP than those with no underlying lung disease.
Collapse
Affiliation(s)
- M Ishijima
- Department of Radiology, Tokyo Medical University Hospital, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Hayashi H, Kawabata Y, Fujii T, Hattori S, Yamamoto Y, Eiji H, Takashi S, Tajima Y. 445. Validation of POSSUM scoring system in abdominal surgery for patients with malignant diseases: A multi-institutional analysis. Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
26
|
Kennoki N, Nakayama H, Itonaga T, Tajima Y, Shiraishi S, Okubo M, Mikami R, Sugahara S, Tokuuye K. Preliminary Results of Feasibility and Toxicities in Intensity Modulated Radiation Therapy With Gemcitabine and S-1 for Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Kawabata Y, Nishi T, Tanaka T, Tajima Y. Safety and Feasibility of a Pancreaticoduodenectomy with Total Meso-Pancreatoduodenum Excision: Analysis in Various Periampullary Disorders. Hepatogastroenterology 2014; 61:821-827. [PMID: 26176080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND/AIMS This study aimed to evaluate the safety and feasibility of a pancreaticoduodenectomy with total meso-pancreatoduodenum excision (tMPDe) as an new anatomical concept. METHODOLOGY A total of 90 patients underwent PD for various periampullary diseases. Of these, 52 patients received a conventional PD (cPD), while 38 patients underwent a tMPDe. Surgical outcomes were compared between the two study groups. RESULTS Operative time was equivalent in the two groups; however, the estimated blood loss (cPD, 1360 ml; tMPDe, 995 ml; median, P = 0.026) and blood transfusion rate (cPD, 63%; tMPDe, 31% ; P = 0.001) were significantly decreased in tMPDe. Morbidity had no significant difference between cPD and tMPDe, and tMPDe showed no characteristic complications. With regard to oncological aspects, tMPDe was superior to cPD. Risk factors analysis revealed the operative time (P = 0.003), estimated blood loss (P < 0.001), and blood transfusion (P < 0.001) to be significant predictive risk factors for postoperative morbidity but not tMPDe procedure (P = 0.794). CONCLUSIONS tMPDe is safe and superior to cPD because it is a bloodless operation with a good oncological outcome: We concluded that tMPDe should be adaptable to various periampullary diseases, including benign and low-grade malignant disorders.
Collapse
|
28
|
Itonaga T, Nakayama H, Tajima Y, Shiraishi S, Mikami Y, Okubo M, Sugahara S, Tokuyye K. EP-1424: Can dynamic susceptibly MRI be a potential imaging biomarker after radiotherapy? Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31542-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Kawabata Y, Nishi T, Tanaka T, Yano S, Tajima Y. Distal Pancreatectomy Utilizing a Flexible Stapler Closure Eliminates the Risk of Pancreas-Related Factors for Postoperative Pancreatic Fistula. Eur Surg Res 2013; 50:71-9. [DOI: 10.1159/000349977] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 02/17/2013] [Indexed: 11/19/2022]
|
30
|
Nishino R, Fukuyama T, Tajima Y, Miyashita L, Watanabe Y, Ueda H, Kosaka T. Prior oral exposure to environmental immunosuppressive chemicals methoxychlor, parathion, or piperonyl butoxide aggravates allergic airway inflammation in NC/Nga mice. Toxicology 2013; 309:1-8. [PMID: 23583882 DOI: 10.1016/j.tox.2013.03.018] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 03/28/2013] [Accepted: 03/29/2013] [Indexed: 01/06/2023]
Abstract
BACKGROUND Immunosuppressive environmental chemicals may increase the potency of allergens and thereby play a role in the development of respiratory tract allergies, such as allergic rhinitis and asthma. OBJECTIVES We investigated the association between environmental immunosuppressive chemicals and the allergic airway inflammation development. METHODS We used a mouse model of ovalbumin (OVA)-induced allergic airway inflammation. NC/Nga mice were exposed orally to pesticides parathion (an organophosphate compound) or methoxychlor (an organochlorine compound), or to an insecticide synergist piperonyl butoxide, prior to OVA intraperitoneal sensitization and inhalation challenge. We assessed serum IgE levels, B-cell counts, cytokine production, IgE production in hilar lymph nodes, eosinophil counts, chemokine levels in bronchoalveolar lavage fluid, and cytokine gene expression in the lung. RESULTS Exposure to environmental immunosuppressive chemicals markedly increased serum IgE - IgE-positive B-cells, IgE and cytokines in lymph nodes - eosinophils and chemokines in BALF - IL-10a and IL-17 in the lung. CONCLUSIONS Allergic airway inflammation can be aggravated by prior exposure to immunosuppressive environmental chemicals.
Collapse
Affiliation(s)
- R Nishino
- Laboratory of Immunotoxicology and Acute Toxicology, Toxicology Division, Institute of Environmental Toxicology, Uchimoriya-machi 4321, Joso-shi, Ibaraki 303-0043, Japan
| | | | | | | | | | | | | |
Collapse
|
31
|
Kobayashi N, Mikami R, Nakayama H, Nogi S, Tajima Y, Okubo M, Kanesaka N, Sugahara S, Tokuuye K. Tumor Response After Small Dose of Chemoradiation Therapy in Patients With Esophageal Carcinoma. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 waitfor delay '0:0:5'-- yckn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
34
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null-- gyaq] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
35
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 order by 1-- tjwi] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
36
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 waitfor delay '0:0:5'] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
37
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null,null-- lhhv] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
38
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null-- hldo] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
39
|
|
40
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null-- bbzg] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
41
|
|
42
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 and 3646=4631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
43
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 and 1328=1328-- scxc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
44
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null,null,null,null,null-- rgld] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
45
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null,null,null,null,null-- nqbo] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
46
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null,null,null-- wfpw] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022] Open
|
47
|
|
48
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 and sleep(5)-- spxu] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
49
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null,null,null,null,null-- cuma] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|
50
|
Kawabata Y, Tanaka T, Nishi T, Monma H, Yano S, Tajima Y. Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma. European Journal of Surgical Oncology (EJSO) 2012. [DOI: 10.1016/j.ejso.2012.04.007 union all select null,null#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/30/2022]
|